Gleevec Buoyed By GIST Trial Results; Novartis Will Seek Adjuvant Indication
NCI-sponsored study halted after imatinib meets primary endpoint, rate of recurrence-free survival, in Kit-positive GIST patients.
NCI-sponsored study halted after imatinib meets primary endpoint, rate of recurrence-free survival, in Kit-positive GIST patients.